Bayer: The new DAX leader has a target of €50. Why JPMorgan calls for a potential of 45%!
Reading Time: 2 minutes
The mood can change quickly. Due to legal risks surrounding glyphosate and the patent expiration in the pharmaceutical sector, such as with Xarelto, Bayer has been one of the loser stocks in the DAX in recent years. Now there’s a turnaround following two positive pieces of news. Bayer has achieved a significant success in the late development phase of its anticoagulant Asundexian. The investigational drug has met all primary endpoints regarding efficacy and safety in the pivotal Phase III study OCEANIC-STROKE for the secondary prevention of...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
